Do you want to read an article? Please log in or register.
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Asthma
Related content
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
Asthma
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Drug Des Devel Ther.
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
doi: 10.2147/
RECOMMENDED
Asthma
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility
Respir Med.
Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N
doi: 10.1016/j.rmed.2019.06.004.
Asthma
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Biologics
Haldar P
doi: 10.2147/BTT.S93954.
Asthma
Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults
Expert Opin Drug Metab Toxicol.
Kallur L, Gonzalez-Estrada A, Eidelman F, Dimov V
doi: 10.1080/
RECOMMENDED
Asthma
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
doi: 10.2147/JAA.S319572
Asthma
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Lancet Respir Med.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A
doi: 10.1016/
RECOMMENDED
Asthma
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, Yancey SW
doi: 10.2147/JAA.S298559
RECOMMENDED
Asthma
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S
doi: 10.1016/j.rmed.2019.105806.